Not Yet RecruitingNot Applicable

Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM

500 participantsStarted 2025-07-01

Plain-language summary

Retrospective evaluation of the efficacy and safety of DEB-TACE combined with HAIC versus HAIC alone in patients with unresectable colorectal liver metastases (CRLM)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years
✓. No gender restriction
✓. Pathologically or clinically diagnosed with colorectal liver metastases
✓. Imaging data available within 31 days prior to enrollment, with at least one measurable lesion (according to RECIST criteria)
✓. Patients received only DEB-TACE combined with HAIC or HAIC alone during the observation period
✓. Child-Pugh classification A or B
✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Exclusion criteria

✕. Presence of treatment risks or contraindications to DEB-TACE combined with HAIC or HAIC alone.
✕. Concurrent diagnosis of other malignancies.
✕. Underwent other local treatment modalities during the observation period.
✕. DEB-TACE combined with HAIC or HAIC alone was used as postoperative adjuvant therapy.
✕. Missing relevant examination results before or after treatment.
✕. Incomplete imaging data, making response evaluation impossible.
✕. Follow-up failure due to incorrect or missing patient information, loss to follow-up, or patient refusal.

What they're measuring

Treatment efficacy-PFS

Timeframe: 6-8 weeks after each treatment

Trial details

NCT IDNCT07031570

SponsorPeking University Cancer Hospital & Institute

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-30

Contact for this trial

Aiwei Feng, MD

88196476 ivyfeng_1026@163.com

View on ClinicalTrials.gov More Colorectal Cancer Metastatic trials